Jazz Pharmaceuticals plc (JAZZ) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Dublin, Ireland. The current CEO is Renee D. Gala.
JAZZ has IPO date of 2007-06-01, 2,800 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $12.38B.
Jazz Pharmaceuticals plc is a biopharmaceutical company headquartered in Dublin, Ireland, that identifies, develops, and commercializes pharmaceutical products to address unmet medical needs across the United States, Europe, and international markets. The company maintains a focused portfolio in neuroscience—particularly sleep medicine and movement disorders—and oncology, including hematologic and solid tumors. Key marketed products include Xyrem and Sunosi for narcolepsy-related conditions, Erwinaze for acute lymphoblastic leukemia, Defitelio for hepatic veno-occlusive disease, Vyxeos for acute myeloid leukemia, and Zepzelca for small cell lung cancer. The company also advances several late-stage candidates, including Xywav for narcolepsy and hypersomnia, and compounds targeting essential tremor and post-traumatic stress disorder. Jazz Pharmaceuticals operates through strategic licensing and collaboration agreements with biotechnology partners to enhance its clinical and commercial capabilities.
